Ausgabe 1/2018
Inhalt (11 Artikel)
Immune Checkpoint Blockade: The New Frontier in Cancer Treatment
Jeffrey M. Clarke, Daniel J. George, Stacey Lisi, April K. S. Salama
Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions
Smruthi Vijayaraghavan, Stacy Moulder, Khandan Keyomarsi, Rachel M. Layman
The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma
Eric Sanchez, Emily J. Smith, Moryel A. Yashar, Saurabh Patil, Mingjie Li, Autumn L. Porter, Edward J. Tanenbaum, Remy E. Schlossberg, Camilia M. Soof, Tara Hekmati, George Tang, Cathy S. Wang, Haiming Chen, James R. Berenson
Incorporating DNA Methyltransferase Inhibitors (DNMTis) in the Treatment of Genitourinary Malignancies: A Systematic Review
Michal Chovanec, Fadi Taza, Maitri Kalra, Noah Hahn, Kenneth P. Nephew, Michael J. Spinella, Costantine Albany
Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program
Jill M. Pulley, Rebecca N. Jerome, Martin L. Ogletree, Gordon R. Bernard, Robert R. Lavieri, Nicole M. Zaleski, Charles C. Hong, Jana K. Shirey-Rice, Carlos L. Arteaga, Ingrid A. Mayer, Kenneth J. Holroyd, Rebecca S. Cook
A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients
Maria Alsina, Fernando Rivera, Francisco Javier Ramos, Maica Galán, Rafael López, Pilar García-Alfonso, José Enrique Alés-Martinez, Bernardo Queralt, Antonio Antón, Alfredo Carrato, Cristina Grávalos, Maria José Méndez-Vidal, Carlos López, Inmaculada Ruiz de Mena, Josep Tabernero, Jordi Giralt, Enrique Aranda
Correction to: A Phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients
Maria Alsina, Fernando Rivera, Francisco Javier Ramos, Maica Galán, Rafael López, Pilar García-Alfonso, José Enrique Alés-Martinez, Bernardo Queralt, Antonio Antón, Alfredo Carrato, Cristina Grávalos, Maria José Méndez-Vidal, Carlos López, Inmaculada Ruiz de Mena, Josep Tabernero, Jordi Giralt, Enrique Aranda
Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study
Juan Martin-Liberal, Antonio López-Pousa, Javier Martínez-Trufero, Javier Martín-Broto, Ricardo Cubedo, Javier Lavernia, Andrés Redondo, José Antonio López-Martín, Nùria Mulet-Margalef, Xavier Sanjuan, Òscar M. Tirado, Xavier Garcia-del-Muro
Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC
Mark J. McKeage, Dusan Kotasek, Ben Markman, Manuel Hidalgo, Michael J. Millward, Michael B. Jameson, Dean L. Harris, Robert J. Stagg, Ann M. Kapoun, Lu Xu, Brett G. M. Hughes
Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial
Kazuto Harada, Xuemei Wang, Yusuke Shimodaira, Tara Sagebiel, Manoop S. Bhutani, Jeffrey H. Lee, Brian Weston, Elena Elimova, Quan Lin, Fatemeh G. Amlashi, Dilsa Mizrak Kaya, Anthony Lopez, Mariela A. Blum Murphy, Jack A. Roth, Stephen G. Swisher, Heath D. Skinner, Wayne L. Hofstetter, Jane E. Rogers, Irene Thomas, Dipen M. Maru, Ritsuko Komaki, Garrett Walsh, Jaffer A. Ajani
Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study
Aziz Zaanan, Juliette Palle, Emilie Soularue, Florence Leroy, Samy Louafi, David Tougeron, Sylvain Manfredi, Pascal Artru, Astrid Pozet, Julien Taieb